<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>2340-9894</journal-id>
<journal-title><![CDATA[Ars Pharmaceutica (Internet)]]></journal-title>
<abbrev-journal-title><![CDATA[Ars Pharm]]></abbrev-journal-title>
<issn>2340-9894</issn>
<publisher>
<publisher-name><![CDATA[Universidad de Granada]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S2340-98942018000100004</article-id>
<article-id pub-id-type="doi">10.30827/ars.v59i1.7277</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Revisión de dosieres de heparina y enoxaparina: incumplimiento de la normativa de Costa Rica para el registro sanitario de biosimilares farmacéuticos]]></article-title>
<article-title xml:lang="en"><![CDATA[Heparin and enoxaparin dossiers review: non-compliance of the Costa Rican regulation for the sanitary registration of pharmaceutical biosimilars]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Álvarez Brenes]]></surname>
<given-names><![CDATA[Rebeca]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Zuñiga Villalobos]]></surname>
<given-names><![CDATA[Keren]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Pacheco Molina]]></surname>
<given-names><![CDATA[Jorge Andrés]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Mora Román]]></surname>
<given-names><![CDATA[Juan José]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Universidad de Costa Rica Facultad de Farmacia ]]></institution>
<addr-line><![CDATA[San José ]]></addr-line>
<country>Costa Rica</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Universidad de Costa Rica Facultad de Farmacia Departamento de Farmacia Industrial]]></institution>
<addr-line><![CDATA[San José ]]></addr-line>
<country>Costa Rica</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>03</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>03</month>
<year>2018</year>
</pub-date>
<volume>59</volume>
<numero>1</numero>
<fpage>27</fpage>
<lpage>35</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_arttext&amp;pid=S2340-98942018000100004&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_abstract&amp;pid=S2340-98942018000100004&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_pdf&amp;pid=S2340-98942018000100004&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[RESUMEN  Objetivo: Determinar los aspectos esenciales de la reglamentación de Costa Rica referente al registro sanitario de biosimilares y compararlos con la información brindada en los dosieres de laboratorios fabricantes de heparina y enoxaparina.  Materiales y métodos: Se examinó el Reglamento de Inscripción y Control de Medicamentos Biológicos: RTCR 440:2010. Luego, se solicitaron los dosieres enviados por los laboratorios fabricantes y se comparó su información con respecto a los datos solicitados por el reglamento anterior. Finalmente, se evaluó la importancia de la información solicitada.  Resultados: El RTCR 440:2010 solicita información química, farmacéutica y biológica del producto farmacéutico terminado, resultados sobre seguridad y eficacia, datos administrativos y documentación legal. Para los biosimilares, se debe presentar el ejercicio de biosimilitud y un plan de farmacovigilancia. Esta información no está presente en su totalidad en los dosieres revisados.  Conclusiones: Los productos revisados no cumplen con los requisitos solicitados por el reglamento costarricense en lo que respecta al ejercicio de biosimilitud. Por ende, no fueron presentados para el trámite de sus registros sanitarios ante el Ministerio de Salud de Costa Rica.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[ABSTRACT  Objective: To determine the essential aspects of the Costa Rican regulation concerning the sanitary registration of biosimilars and to compare them with the information provided in the dossiers of laboratories manufacturing heparin and enoxaparin.  Methodology: The regulation for the Registration and Control of Biological Drugs: RTCR 440: 2010 was reviewed. Subsequently, the dossiers sent by the manufacturers were requested, and their information was compared with the data requested by the previous regulation. Finally, the importance of this information was evaluated.  Results: The national regulations require chemical, pharmaceutical and biological information on the finished pharmaceutical product, results on safety and efficacy, administrative data and legal documentation. For biosimilars, the biosimilitude exercise and a pharmacovigilance plan must be presented. This information is not available in its entirety in the reviewed dossiers.  Conclusions: The products reviewed do not meet the requirements of the Costa Rican regulations regarding the biosimilitude exercise. Therefore, they were not submitted for their drugs' applications before the Ministry of Health of Costa Rica.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Biosimilares farmacéuticos]]></kwd>
<kwd lng="es"><![CDATA[heparina]]></kwd>
<kwd lng="es"><![CDATA[enoxaparina]]></kwd>
<kwd lng="en"><![CDATA[Biosimilar pharmaceuticals]]></kwd>
<kwd lng="en"><![CDATA[heparin]]></kwd>
<kwd lng="en"><![CDATA[enoxaparin]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Tejerina]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Medina]]></surname>
<given-names><![CDATA[U]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Fármacos Biotecnológicos, Biosimilares, Bioequivalentes]]></article-title>
<source><![CDATA[Actualidad en Farmacología y Terapéutica]]></source>
<year>2012</year>
<volume>10</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>233-8</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="book">
<collab>European Medicines Agency</collab>
<source><![CDATA[Lo que debe saber sobre los medicamentos biosimilares]]></source>
<year>2013</year>
<publisher-loc><![CDATA[Londres ]]></publisher-loc>
<publisher-name><![CDATA[EMA]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Avalos]]></surname>
<given-names><![CDATA[BR]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Bring on the Biosimilars!]]></article-title>
<source><![CDATA[Biol Blood Marrow Transplant]]></source>
<year>2015</year>
<volume>21</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>1859-60</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hughes]]></surname>
<given-names><![CDATA[DA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Biosimilars: Evidential Standards for Health Technology Assessment]]></article-title>
<source><![CDATA[Clin Pharmacol Ther]]></source>
<year>2010</year>
<volume>87</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>257-61</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Minghetti]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Rocco]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Del]]></surname>
<given-names><![CDATA[Vecchio L]]></given-names>
</name>
<name>
<surname><![CDATA[Locatelli]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Biosimilars and Regulatory Authorities]]></article-title>
<source><![CDATA[Nephron Clin Pract]]></source>
<year>2011</year>
<volume>117</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>c1-7</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Olech]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Biosimilars: Rationale and current regulatory landscape]]></article-title>
<source><![CDATA[Semin Arthritis Rheum]]></source>
<year>2016</year>
<volume>45</volume>
<page-range>S1-S10</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Reglamento de Inscripción y Control de Medicamentos Biológicos RTCR 440]]></article-title>
<source><![CDATA[La Gaceta]]></source>
<year>2012</year>
<volume>59</volume>
</nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mysler]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Pineda]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Horiuchi]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Singh]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Mahgoub]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Coindreau]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Clinical and regulatory perspectives on biosimilar therapies and intended copies of biologics in rheumatology]]></article-title>
<source><![CDATA[Rheumatol Int]]></source>
<year>2016</year>
<volume>36</volume>
<page-range>613-25</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rugo]]></surname>
<given-names><![CDATA[HS]]></given-names>
</name>
<name>
<surname><![CDATA[Linton]]></surname>
<given-names><![CDATA[KM]]></given-names>
</name>
<name>
<surname><![CDATA[Cervi]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Rosenberg]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Jacobs]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A clinician's guide to biosimilars in oncology]]></article-title>
<source><![CDATA[Cancer Treat Rev]]></source>
<year>2016</year>
<volume>46</volume>
<page-range>73-9</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hirsh]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Anand]]></surname>
<given-names><![CDATA[SS]]></given-names>
</name>
<name>
<surname><![CDATA[Halperin]]></surname>
<given-names><![CDATA[JL]]></given-names>
</name>
<name>
<surname><![CDATA[Fuster]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Guide to Anticoagulant Therapy: Heparin A Statement for Healthcare Professionals From the American Heart Association]]></article-title>
<source><![CDATA[Arterioscler, Thromb, Vasc Biol]]></source>
<year>2001</year>
<volume>103</volume>
<numero>24</numero>
<issue>24</issue>
<page-range>2994-3018</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fu]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Suflita]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Linhardt]]></surname>
<given-names><![CDATA[RJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Bioengineered heparins and heparan sulfates]]></article-title>
<source><![CDATA[Adv Drug Delivery Rev]]></source>
<year>2016</year>
<volume>97</volume>
<page-range>237-49</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Nandurkar]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Chong]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Salem]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Gallus]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Ferro]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[McKinnon]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Low-molecular-weight heparin biosimilars: potential implications for clinical practice]]></article-title>
<source><![CDATA[Intern Med J]]></source>
<year>2014</year>
<volume>44</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>497-500</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Abad Hernández]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Andreu]]></surname>
<given-names><![CDATA[JL]]></given-names>
</name>
<name>
<surname><![CDATA[Caracuel Ruiz]]></surname>
<given-names><![CDATA[MÁ]]></given-names>
</name>
<name>
<surname><![CDATA[Belmonte]]></surname>
<given-names><![CDATA[Serrano MA]]></given-names>
</name>
<name>
<surname><![CDATA[Díaz-González]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Moreno]]></surname>
<given-names><![CDATA[Muelas JV]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Documento de posicionamiento de la Sociedad Española de Reumatología sobre fármacos biosimilares]]></article-title>
<source><![CDATA[Reumatología Clínica]]></source>
<year>2015</year>
<volume>11</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>269-78</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Reglamento de Inscripción, Control, Importación y Publicidad de Medicamentos]]></article-title>
<source><![CDATA[La Gaceta]]></source>
<year>2000</year>
<volume>42</volume>
</nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Azevedo]]></surname>
<given-names><![CDATA[VF]]></given-names>
</name>
<name>
<surname><![CDATA[Mysler]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Aceituno Álvarez]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Hughes]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Flores-Murrieta]]></surname>
<given-names><![CDATA[FJ]]></given-names>
</name>
<name>
<surname><![CDATA[Ruiz de Castilla]]></surname>
<given-names><![CDATA[EM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Recommendations for the regulation of biosimilars and their implementation in Latin America]]></article-title>
<source><![CDATA[Generics and Biosimilars Initiative Journal]]></source>
<year>2014</year>
<volume>3</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>143-8</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="book">
<collab>Consejo Internacional de Armonización de los requisitos técnicos para el registro de medicamentos de uso humano</collab>
<source><![CDATA[ICH Q5E:Comparability of Biotechnological/Biological Products Subject to Changes in Their Manufacturing Process]]></source>
<year>2003</year>
<publisher-loc><![CDATA[Ginebra ]]></publisher-loc>
<publisher-name><![CDATA[ICH]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="book">
<collab>Committee for Medicinal Products for Human Use</collab>
<source><![CDATA[Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues]]></source>
<year>2014</year>
<publisher-loc><![CDATA[Londres ]]></publisher-loc>
<publisher-name><![CDATA[EMA]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="book">
<collab>Health Canada</collab>
<source><![CDATA[Information and Submission Requirements for Biosimilar Biologic Drugs]]></source>
<year>2016</year>
<publisher-loc><![CDATA[Ontario ]]></publisher-loc>
<publisher-name><![CDATA[Health Canada]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="book">
<collab>European Medicines Agency</collab>
<source><![CDATA[Guidelines on Pharmacovigilance for Medicinal Products for Human Use]]></source>
<year>2008</year>
<publisher-loc><![CDATA[Londres ]]></publisher-loc>
<publisher-name><![CDATA[EMA]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[YM]]></given-names>
</name>
<name>
<surname><![CDATA[Chow]]></surname>
<given-names><![CDATA[AT]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Development of biosimilars-pharmacokinetic and pharmacodynamic considerations]]></article-title>
<source><![CDATA[J Biopharm Stat]]></source>
<year>2010</year>
<volume>20</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>46-61</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="book">
<collab>World Health Organization</collab>
<source><![CDATA[Guidelines on Evaluation of Similar Biotherapeutic Products]]></source>
<year>2009</year>
<publisher-loc><![CDATA[Ginebra ]]></publisher-loc>
<publisher-name><![CDATA[WHO]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="book">
<collab>Committee for Medicinal Products for Human Use</collab>
<source><![CDATA[Guideline on similar biological medicinal products]]></source>
<year>2014</year>
<publisher-loc><![CDATA[Londres ]]></publisher-loc>
<publisher-name><![CDATA[EMA]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="book">
<collab>US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research</collab>
<source><![CDATA[Scientific Considerations in Demonstrating Biosimilarity to a Reference Product: guidance for Industry]]></source>
<year>2015</year>
<publisher-loc><![CDATA[Maryland ]]></publisher-loc>
<publisher-name><![CDATA[FDA]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="">
<collab>Generics and Biosimilars Initiative</collab>
<source><![CDATA[Enoxaparin biosimilar or not]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B25">
<label>25</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mourier]]></surname>
<given-names><![CDATA[PAJ]]></given-names>
</name>
<name>
<surname><![CDATA[Agut]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Souaifi-Amara]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Herman]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Viskov]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Analytical and statistical comparability of generic enoxaparins from the US market with the originator product]]></article-title>
<source><![CDATA[J Pharm Biomed Anal]]></source>
<year>2015</year>
<volume>115</volume>
<page-range>431-42</page-range></nlm-citation>
</ref>
<ref id="B26">
<label>26</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Harenberg]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Overview on guidelines and recommendations for generic low-molecular-weight heparins]]></article-title>
<source><![CDATA[Thromb Res]]></source>
<year>2011</year>
<volume>127</volume>
<numero>Suplemento 3</numero>
<issue>Suplemento 3</issue>
<page-range>S100-4</page-range></nlm-citation>
</ref>
<ref id="B27">
<label>27</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mourão]]></surname>
<given-names><![CDATA[PAS]]></given-names>
</name>
<name>
<surname><![CDATA[Glauser]]></surname>
<given-names><![CDATA[BF]]></given-names>
</name>
<name>
<surname><![CDATA[Vairo]]></surname>
<given-names><![CDATA[BC]]></given-names>
</name>
<name>
<surname><![CDATA[Pereira]]></surname>
<given-names><![CDATA[MS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Debate de una Propuesta sobre los Biosimilares de Enoxaparina en Brasil]]></article-title>
<source><![CDATA[Arq Bras Cardiol]]></source>
<year>2012</year>
<volume>98</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>e11-4</page-range></nlm-citation>
</ref>
<ref id="B28">
<label>28</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Harenberg]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Kalodiki]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Walenga]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Ensuring safety of biosimilar low-molecular-weight heparins:a consensus statement of the International Union of Angiology]]></article-title>
<source><![CDATA[Int Angiol]]></source>
<year>2012</year>
<volume>31</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>101-4</page-range></nlm-citation>
</ref>
<ref id="B29">
<label>29</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Minghetti]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Cilurzo]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Franzé]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Musazzi]]></surname>
<given-names><![CDATA[UM]]></given-names>
</name>
<name>
<surname><![CDATA[Itri]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Low molecular weight heparins copies:are they considered to be generics or biosimilars?]]></article-title>
<source><![CDATA[Drug Discovery Today]]></source>
<year>2013</year>
<volume>18</volume>
<numero>5-6</numero>
<issue>5-6</issue>
<page-range>305-11</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
